Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Browsing Tag

first

34 posts
RRoche
Roche’s Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy
Read More

Roche’s Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy

  • 2026-11-16
Approval based on phase III MAJESTY results demonstrating Gazyva/Gazyvaro superiority over tacrolimus in achieving complete remission of proteinuria…
ZZürich
Venture Challenge at ETH Zurich
Read More

Venture Challenge at ETH Zurich

  • 2026-11-06
Accelerate your startup project with the support of successful founders and industry leaders! Venture Challenge at ETH is…
RRoche
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]
Read More

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]

  • 2026-10-22
Ad hoc announcement pursuant to Art. 53 LR Basel, 22 October 2026 Roche continues strong momentum in the…
RRoche
FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
Read More

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

  • 2026-10-16
FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye…
NNovartis
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
Read More

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

  • 2026-10-07
In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12…
RRoche
Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis
Read More

Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis

  • 2026-09-30
Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2)…
SSwitzerland
How 'Footuro' Works: The Project Linking Switzerland and Romano
Read More

How ‘Footuro’ Works: The Project Linking Switzerland and Romano

  • 2026-09-25
The Azzurri midfielder will likely have to compensate the federation: over the years, they spent between 25,000 and…
SSwitzerland
SERV, Swiss Export Risk Insurance, Supports Guarantee of USD 212.5 Million for Capex of First Phosphate Mine Project in Quebec, Canada
Read More

SERV, Swiss Export Risk Insurance, Supports Guarantee of USD 212.5 Million for Capex of First Phosphate Mine Project in Quebec, Canada

  • 2026-09-16
Saguenay, Québec–(Newsfile Corp. – September 16, 2026) – First Phosphate Corp. (NASDAQ: PHOS) (CSE: PHOS) (OTCQX: FRSPF) (FSE:…
SSwitzerland
SERV, Swiss Export Risk Insurance, Supports Guarantee of USD 212.5 Million for Capex of First Phosphate Mine Project in Quebec, Canada
Read More

SERV, Swiss Export Risk Insurance, Supports Guarantee of USD 212.5 Million for Capex of First Phosphate Mine Project in Quebec, Canada

  • 2026-09-16
Saguenay, Québec–(Newsfile Corp. – September 16, 2026) – First Phosphate Corp. (NASDAQ: PHOS) (CSE: PHOS) (OTCQX: FRSPF) (FSE:…
BBern
HS Football GOTW Week 3: A thriller of a Craven County Championship
Read More

HS Football GOTW Week 3: A thriller of a Craven County Championship

  • 2026-09-05
The above video is our WITN+ livestream and may not reflect the content in this story. NEW BERN,…
SSwitzerland
Colb Becomes Switzerland’s First Provider of Pre-IPO Structured Products as Ledger-Based Securities
Read More

Colb Becomes Switzerland’s First Provider of Pre-IPO Structured Products as Ledger-Based Securities

  • 2026-08-12
Colb Asset SA operates within a Swiss-compliant legal and regulatory framework for the offering of tokenized pre-IPO structured…
RRoche
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
Read More

CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)

  • 2026-07-24
Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye…
Switzerland
www.europesays.com